Abstract
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth. The 1980s saw for the first time the identification, purification, and sequencing of the two prototypic heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, 22 structurally-related members of the FGF family and differenent classes of FGF receptors have been identified. Several experimental evidences point to a role for various FGFs in the neovascularization process that takes place in inflammation, angioproliferative diseases, and tumor growth. Thus, the FGF/FGF receptor system represents a target for the development of antiangiogenic therapies. Purpose of this review is to summarize the different modalities that have been approached to impair the proangiogenic activity of the FGF/FGF receptor system and discuss their possible therapeutic implications.
Keywords: Angiogenesis, endothelium, FGF, FGF receptors, inhibitors
Current Pharmaceutical Design
Title: Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Volume: 13 Issue: 20
Author(s): M. Rusnati and M. Presta
Affiliation:
Keywords: Angiogenesis, endothelium, FGF, FGF receptors, inhibitors
Abstract: Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth. The 1980s saw for the first time the identification, purification, and sequencing of the two prototypic heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, 22 structurally-related members of the FGF family and differenent classes of FGF receptors have been identified. Several experimental evidences point to a role for various FGFs in the neovascularization process that takes place in inflammation, angioproliferative diseases, and tumor growth. Thus, the FGF/FGF receptor system represents a target for the development of antiangiogenic therapies. Purpose of this review is to summarize the different modalities that have been approached to impair the proangiogenic activity of the FGF/FGF receptor system and discuss their possible therapeutic implications.
Export Options
About this article
Cite this article as:
M. Rusnati and M. Presta , Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies, Current Pharmaceutical Design 2007; 13 (20) . https://dx.doi.org/10.2174/138161207781039689
DOI https://dx.doi.org/10.2174/138161207781039689 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued) The Indolylcoumarin COUFIN Exhibits Potent Activity Against Renal Carcinoma Cells without Affecting Hematopoietic System
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics of Oxazaphosphorines and its Clinical Implications
Current Pharmacogenomics Patent Selections
Recent Patents on Biotechnology An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Subcellular Analysis of the Platelet Proteome
Current Proteomics GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism